Business
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDAIn December 2022, FDA increased the maximum number
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDAIn December 2022, FDA increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") under its Jaguar Animal Health tradename for the veterinary market, today announced that the Company is exhibiting at the Veterinary Cancer Society (VCS) Collaborative Conference, which takes place April 19-22, 2023 in Cancun, Mexico, as part of ongoing promotional activities for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S.Effective December 14, 2022, the FDA's Center for Veterinary Medicine increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000. \"The FDA conducts a reassessment of the ‘small numbers of animals' definition approximately every 5 years,\" said Michael Guy, DVM, MS, PhD, Jaguar Health's vice president of preclinical and nonclinical studies, \"and we're pleased that, as a result of the most recent reassessment, the size of the addressable annual market for Canalevia-CA1 has now increased from 70,000 to 80,000 dogs.\"The Minor Use and Minor Species (MUMS) Animal Health Act of 2004MUMS is modeled on the orphan-drug designation for human drug development. The purpose of the MUMS Act is to encourage the development and availability of animal drugs intended either as a minor use (a use for a disease which occurs infrequently or in limited geographic areas) in a major species (dogs, cats, cattle, horses, chickens, turkeys, and pigs) or for use in minor species (defined as all animals other than humans that are not one of the seven major species).About Chemotherapy-induced Diarrhea (CID) in DogsDue to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have f...